EA200100135A1 - Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов - Google Patents

Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов

Info

Publication number
EA200100135A1
EA200100135A1 EA200100135A EA200100135A EA200100135A1 EA 200100135 A1 EA200100135 A1 EA 200100135A1 EA 200100135 A EA200100135 A EA 200100135A EA 200100135 A EA200100135 A EA 200100135A EA 200100135 A1 EA200100135 A1 EA 200100135A1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
useful
quinolin
compounds
treatment agents
Prior art date
Application number
EA200100135A
Other languages
English (en)
Inventor
Сузан Дебора Ла Грика
Джозеф Питер Лиссикэйтос
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200100135A1 publication Critical patent/EA200100135A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Abstract

Настоящее изобретение относится к соединениям формулы (1) и к их фармацевтически приемлемым солям, пролекарствам и сольватам, где R, R, R, R, R, R, R, R, R, Rи Rтакие, как определено в описании. Вышеуказанные соединения формулы (1) полезны в лечении гиперпролиферативных расстройств, таких как рак, у млекопитающих. Изобретение также относится к фармацевтическим композициям, содержащим соединения формулы (1), и к способам ингибирования аномального роста клеток, включая рак, у млекопитающего путем введения соединений формулы (1) млекопитающему, которому требуется такое лечение.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100135A 1998-08-27 1999-08-06 Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов EA200100135A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9814598P 1998-08-27 1998-08-27
PCT/IB1999/001398 WO2000012499A1 (en) 1998-08-27 1999-08-06 Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents

Publications (1)

Publication Number Publication Date
EA200100135A1 true EA200100135A1 (ru) 2001-08-27

Family

ID=22267481

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100135A EA200100135A1 (ru) 1998-08-27 1999-08-06 Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов

Country Status (40)

Country Link
US (3) US6150377A (ru)
EP (1) EP1107963B1 (ru)
JP (1) JP3495706B2 (ru)
KR (1) KR20010072991A (ru)
CN (1) CN1314904A (ru)
AP (1) AP2001002079A0 (ru)
AT (1) ATE321037T1 (ru)
AU (1) AU4925499A (ru)
BG (1) BG105365A (ru)
BR (1) BRPI9913138B8 (ru)
CA (2) CA2578326C (ru)
CO (1) CO5130017A1 (ru)
CZ (1) CZ2001660A3 (ru)
DE (1) DE69930518T2 (ru)
DZ (1) DZ2880A1 (ru)
EA (1) EA200100135A1 (ru)
EE (1) EE200100118A (ru)
ES (1) ES2259237T3 (ru)
GE (1) GEP20033001B (ru)
GT (1) GT199900140A (ru)
HK (1) HK1039123A1 (ru)
HR (1) HRP20010142A2 (ru)
HU (1) HUP0103228A3 (ru)
ID (1) ID27562A (ru)
IL (1) IL141239A0 (ru)
IS (1) IS5818A (ru)
MA (1) MA26680A1 (ru)
NO (1) NO20010964L (ru)
NZ (1) NZ509372A (ru)
OA (1) OA11645A (ru)
PA (1) PA8480101A1 (ru)
PE (1) PE20000986A1 (ru)
PL (1) PL346426A1 (ru)
SK (1) SK2442001A3 (ru)
SV (1) SV1999000141A (ru)
TN (1) TNSN99162A1 (ru)
TR (1) TR200101343T2 (ru)
UY (1) UY25682A1 (ru)
WO (1) WO2000012499A1 (ru)
ZA (1) ZA200101173B (ru)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114503A1 (en) * 1997-06-16 2003-06-19 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
PL193296B1 (pl) * 1998-07-06 2007-01-31 Janssen Pharmaceutica Nv Zastosowanie inhibitora białkowej transferazy farnezylowej
EP1107962B1 (en) * 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
EE200100118A (et) * 1998-08-27 2002-06-17 Pfizer Products Inc. Vähivastaste vahenditena kasulikud alkünüül-asendatud kinoliin-2-ooni derivaadid
ID29584A (id) 1999-02-11 2001-09-06 Pfizer Prod Inc Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
CA2397558A1 (en) 2000-02-24 2001-08-30 Janssen Pharmaceutica N.V. Dosing regimen
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
WO2002024682A1 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
EP1322636A1 (en) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives
JP4974439B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
DE60135919D1 (de) 2000-09-25 2008-11-06 Janssen Pharmaceutica Nv Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
US7153958B2 (en) 2000-11-21 2006-12-26 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
JP2004516287A (ja) 2000-12-19 2004-06-03 ファイザー・プロダクツ・インク ６−［（４−クロロ−フェニル）−ヒドロキシ−（３−メチル−３ｈ−イミダゾール−４−イル）−メチル］−４−（３−エチニル−フェニル）−１−メチル−１ｈ−キノリン−２−オン，２，３−ジヒドロキシブタン二酸塩の結晶形および製造方法
ATE319704T1 (de) * 2000-12-27 2006-03-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
MXPA03008205A (es) 2001-03-12 2004-01-29 Janssen Pharmaceutica Nv Procedimiento para la preparacion de compuestos de imidazol.
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
WO2002098425A1 (en) * 2001-06-04 2002-12-12 Cytovia, Inc. Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1408971A4 (en) 2001-06-21 2006-01-25 Ariad Pharma Inc NEW QUINOLINES AND THEIR USES
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
ES2323265T3 (es) 2001-12-19 2009-07-10 Janssen Pharmaceutica Nv Derivados de quinolina condensados en 1,8 sustituidos con triazoles unidos por el carbono como inhibidores de la farnesil-transferasa.
US7241777B2 (en) 2002-03-22 2007-07-10 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
AU2003229688B2 (en) 2002-04-15 2009-07-30 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
BR0317548A (pt) * 2002-12-19 2005-11-22 Pfizer Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
EP1691812A4 (en) 2003-11-20 2010-01-13 Childrens Hosp Medical Center GTPASE INHIBITORS AND METHOD OF USE
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
AU2005276132B2 (en) * 2004-08-26 2011-09-29 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
RS51362B (en) 2004-08-26 2011-02-28 Pfizer Inc. ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
MX2007001986A (es) * 2004-08-26 2007-05-10 Pfizer Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
SI2362218T1 (sl) 2004-11-05 2014-12-31 Janssen Pharmaceutica N.V. Postopki za spremljanje učinkovitosti inhibitorjev farneziltransferaze
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US7826982B2 (en) 2005-07-29 2010-11-02 Children's Hospital Medical Center Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE
ES2546069T3 (es) 2005-09-07 2015-09-18 Amgen Fremont Inc. Anticuerpos monoclonales humanos para quinasa-1 de tipo receptor de activina (ALK-1)
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2007075923A2 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
DK2021335T3 (da) 2006-04-20 2011-09-05 Janssen Pharmaceutica Nv Heterocykliske forbindelser som C-FMS-kinasehæmmere
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
PE20080074A1 (es) 2006-04-20 2008-02-11 Janssen Pharmaceutica Nv Derivados de amida como agentes inhibidores de la quinasa c-fms
EP2021338A1 (en) 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
DK2056874T3 (da) 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
WO2008112525A2 (en) * 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
MX2011005096A (es) 2008-11-13 2011-11-18 Link Medicine Corp Derivados de azaquinolinona y usos de los mismos.
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
EP2401613A2 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2011109572A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
IN2015DN00659A (ru) 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
CN108371711A (zh) 2015-08-17 2018-08-07 库拉肿瘤学公司 使用法尼基转移酶抑制剂治疗癌症患者的方法
US20180371551A1 (en) 2015-12-03 2018-12-27 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
SG11201903786UA (en) 2016-11-03 2019-05-30 Kura Oncology Inc Farnesyltransferase inhibitors for use in methods of treating cancer
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
TWI738314B (zh) 2017-02-21 2021-09-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
JP7325400B2 (ja) 2017-08-07 2023-08-14 クラ オンコロジー， インコーポレイテッド ファルネシルトランスフェラーゼ阻害剤を用いてがんを治療する方法
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
AU2019372141A1 (en) 2018-11-01 2021-05-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220071941A1 (en) 2018-12-21 2022-03-10 Kura Oncology, Inc. Therapies for squamous cell carcinomas
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
KR20210144778A (ko) 2019-03-29 2021-11-30 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용한 편평 세포 암종의 치료 방법
WO2020205387A1 (en) 2019-04-01 2020-10-08 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
IL123568A (en) * 1995-12-08 2001-08-08 Janssen Pharmaceutica Nv History (Imidazole - 5Il) Methyl-2-quinolinone inhibitors of Prenzyl transferase, their preparation, pharmaceutical preparations containing them and their preparation and drugs containing them
EE200100118A (et) * 1998-08-27 2002-06-17 Pfizer Products Inc. Vähivastaste vahenditena kasulikud alkünüül-asendatud kinoliin-2-ooni derivaadid

Also Published As

Publication number Publication date
MA26680A1 (fr) 2004-12-20
BRPI9913138B8 (pt) 2016-05-17
CA2578326C (en) 2009-11-24
US6294552B1 (en) 2001-09-25
UY25682A1 (es) 2000-03-31
DE69930518D1 (de) 2006-05-11
NZ509372A (en) 2003-08-29
AU4925499A (en) 2000-03-21
KR20010072991A (ko) 2001-07-31
NO20010964D0 (no) 2001-02-26
TNSN99162A1 (fr) 2005-11-10
EP1107963A1 (en) 2001-06-20
CN1314904A (zh) 2001-09-26
HUP0103228A2 (hu) 2002-02-28
EE200100118A (et) 2002-06-17
CZ2001660A3 (cs) 2002-05-15
NO20010964L (no) 2001-04-26
US6150377A (en) 2000-11-21
HK1039123A1 (zh) 2002-04-12
CA2341690C (en) 2007-04-17
EP1107963B1 (en) 2006-03-22
CA2341690A1 (en) 2000-03-09
US6579887B2 (en) 2003-06-17
US20020128287A1 (en) 2002-09-12
JP3495706B2 (ja) 2004-02-09
PA8480101A1 (es) 2003-06-30
DZ2880A1 (fr) 2003-12-15
ATE321037T1 (de) 2006-04-15
ES2259237T3 (es) 2006-09-16
HUP0103228A3 (en) 2003-01-28
IS5818A (is) 2001-01-19
IL141239A0 (en) 2002-03-10
CO5130017A1 (es) 2002-02-27
BR9913138B1 (pt) 2013-11-05
SK2442001A3 (en) 2002-10-08
ID27562A (id) 2001-04-12
SV1999000141A (es) 2000-07-06
BG105365A (en) 2001-11-30
PE20000986A1 (es) 2000-09-30
PL346426A1 (en) 2002-02-11
TR200101343T2 (tr) 2001-09-21
OA11645A (en) 2004-11-16
WO2000012499A1 (en) 2000-03-09
JP2002523504A (ja) 2002-07-30
GEP20033001B (en) 2003-06-25
GT199900140A (es) 2001-02-14
AP2001002079A0 (en) 2001-03-31
BR9913138A (pt) 2001-05-08
DE69930518T2 (de) 2006-09-21
CA2578326A1 (en) 2000-03-09
ZA200101173B (en) 2002-04-12
HRP20010142A2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
EA200100135A1 (ru) Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
EA200001146A1 (ru) Производные изотиазола, применимые в качестве противораковых агентов
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
EA200201277A1 (ru) Замещенные бициклические производные для лечения аномального роста клеток
EA200200509A1 (ru) Новые производные бензоимидазола, используемые в качестве антипролиферативного средства
DE69923849D1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
PT928788E (pt) Compostos farmaceuticamente activos
EA200100766A1 (ru) Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов
EA200100983A1 (ru) Производные 13-метилэритромицина
EA200500814A1 (ru) Производные пирролопиримидина
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
RU2203274C2 (ru) Спироциклические ингибиторы металлопротеаз
EA200100623A1 (ru) Кетолидные антибиотики
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
EA200000996A1 (ru) Конденсированные с арилом азаполициклические соединения
EA200001029A1 (ru) Производные гигромицина
DE69330601D1 (de) Serotoninergische ergolin derivate
EA200200292A1 (ru) Производные гигромицина
EA200001028A1 (ru) Производные 2"-деоксигигромицина
ATE222583T1 (de) Derivate substituierter amidinonaphthylester
EA200100444A1 (ru) Производные гигромицина а в качестве антибактериальных агентов